The use of biomarkers in oncology has been much more extensive than in other diseases for more than 30 years. Their use has evolved beyond the research laboratory to more routine clinical use as in diagnosis, monitoring of disease status, and treatment efficacy.

With the advances in molecular biology, other biomarkers than the "classical" serum markers are being developed for clinical use: gene mutations, microRNA, circulating tumor cells, circulating DNA, and others currently in research. Biomarkers such as these are currently being used for prediction potential “at risk” for disease as well as response to therapy (predictive biomarkers) and for disease prognosis (prognostic biomarkers).

In oncological routine, the correlation of biomarker levels with the clinical status and medical imaging methods is of great significance. The purpose of the correlation is twofold: providing a sequential and/or more specific diagnostics and keeping these procedures within affordable economical limits.

We invite research scientists and other investigators to contribute original research articles as well as review articles that address the optimal use of biomarkers in oncology.

Potential topics include, but are not limited to:

• Biomarkers measurement and their impact on the disease state (diagnostics and followup)
• Circulation tumor cells and circulation tumor DNA as prognostic and predictive markers
• MicroRNA as prognostic markers in cancer
• Molecular markers to predict clinical outcome and toxicity in cancer
• Biomarkers for the selection of therapy, prediction, and monitoring
• Genetics and biomarkers in personalization of cancer treatment
• Correlation of biomarkers and medical imaging
• Perspectives on the use of biomarkers in oncology